Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide in Relapsed or Refractory NK/T Cell Lymphoma
NCT04038411Phase 4Unknown
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of tislelizumab, tucidinostat, lenalidomide, etoposide in natural killer/T-cell lymphoma (NKTL). Status: unknown.
02
Drugs
tislelizumabtucidinostatlenalidomideetoposide
03
Conditions
natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT04038411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04038411.